<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657381</url>
  </required_header>
  <id_info>
    <org_study_id>NTP-F520-001</org_study_id>
    <nct_id>NCT03657381</nct_id>
  </id_info>
  <brief_title>Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520</brief_title>
  <official_title>Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520 by Advanced Tumor Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong New Time Pharmaceutical Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong New Time Pharmaceutical Co., LTD</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recombinant Programmed death-1(PD-1) humanized monoclonal antibody injection (company code:&#xD;
      F520) is joint developed by Shandong New Time Pharmaceutical Co., LTD., it is the&#xD;
      reorganization of deoxyribonucleic acid (DNA) technology in the Chinese hamster ovary (CHO)&#xD;
      cells express system expressed in a immunoglobulin G1 (IgG1) kappa type single resistance to&#xD;
      predominate. F520 had the different new amino acid sequence and molecular structure compared&#xD;
      with two marketed PD-1 monoclonal antibody injection and got the approval of China Food and&#xD;
      Drug Administration (CFDA) for clinical trial.Pharmaceutical research indicated F520 cell&#xD;
      strain had security source, production process is stable, quality can control, preparation&#xD;
      stability, has good compatibility with packaging materials, it has the condition of&#xD;
      industrialization, can prepare investigational medicinal product with safety, effective, and&#xD;
      controlled quality for clinical research.Pharmacodynamics study show the targets and&#xD;
      mechanisms of F520is clear, tumor suppression effect is obvious.Toxicology studies show this&#xD;
      product in high doses with low toxic, and the toxic is reversible, the most common toxicity&#xD;
      is specific to the drug action mechanism.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">October 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 8, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.</measure>
    <time_frame>1.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PD-1 receptor occupancy of blood</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) by irRC/ RECIST 1.1/RANO/cheson2007</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) by irRC/ RECIST 1.1/RANO/cheson2007</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) after single dose injection of Anti-PD-1 Monoclonal Antibody (mAb)</measure>
    <time_frame>1.5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Time (Tmax) after single dose injection of Anti-PD-1 mAb</measure>
    <time_frame>1.5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) after single dose injection of Anti-PD-1 mAb</measure>
    <time_frame>1.5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 after single dose injection of Recombinant Humanized Anti-PD-1 mAb</measure>
    <time_frame>1.5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma clearance (CL) after single dose injection of Anti-PD-1 mAb</measure>
    <time_frame>1.5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (V) after single dose injection of Anti-PD-1 mAb</measure>
    <time_frame>1.5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Plasma Concentration (Cmin) of steady state after multiple dose injection of Anti-PD-1 mAb</measure>
    <time_frame>1.5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Plasma Concentration (Cavg) of steady state after multiple dose injection of Anti-PD-1 mAb</measure>
    <time_frame>1.5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>degree of fluctuation (DF) of steady state after multiple dose injection of Anti-PD-1 mAb</measure>
    <time_frame>1.5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of steady state (Vss) after multiple dose injection of Anti-PD-1 mAb</measure>
    <time_frame>1.5years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>correlation analysis of Tumor marker and therapeutic effect</measure>
    <time_frame>3 years</time_frame>
    <description>Tumor markers include PD-L1、TMB、MSI、dMMR</description>
  </other_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Advanced Solid Tumor，Recurrent Solid Tumor，Lymphoma，Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>F520 0.2mg/kg single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F520 0.2mg/kg single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F520 1.0mg/kg single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F520 1.0mg/kg single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F520 3.0mg/kg single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F520 3.0mg/kg single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F520 200mg/times single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F520 200mg/times single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F520 10mg/kg single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F520 10mg/kg single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F520 1mg/kg multiple dosing, every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F520 1mg/kg every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F520 3mg/kg multiple dosing, every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F520 3mg/kg every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F520 200mg/times multiple dosing, every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F520 200mg/times every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F520 10mg/kg multiple dosing, every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F520 10mg/kg every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F520 3mg/kg multiple dosing, every 3 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F520 3mg/kg every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F520 200mg/times multiple dosing, every 3 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F520 200mg/times every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection</intervention_name>
    <description>Biological: F520 single-dose:0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 200mg/times, 10mg/kg; multiple dosing: 1mg/kg, 3mg/kg, 200mg/times, 10mg/kg, treat every 2 weeks; multiple dosing: 3mg/kg, 200mg/times, treat every 3 weeks.</description>
    <arm_group_label>F520 0.2mg/kg single-dose</arm_group_label>
    <arm_group_label>F520 1.0mg/kg single-dose</arm_group_label>
    <arm_group_label>F520 10mg/kg multiple dosing, every 2 weeks</arm_group_label>
    <arm_group_label>F520 10mg/kg single-dose</arm_group_label>
    <arm_group_label>F520 1mg/kg multiple dosing, every 2 weeks</arm_group_label>
    <arm_group_label>F520 200mg/times multiple dosing, every 2 weeks</arm_group_label>
    <arm_group_label>F520 200mg/times multiple dosing, every 3 weeks</arm_group_label>
    <arm_group_label>F520 200mg/times single-dose</arm_group_label>
    <arm_group_label>F520 3.0mg/kg single-dose</arm_group_label>
    <arm_group_label>F520 3mg/kg multiple dosing, every 2 weeks</arm_group_label>
    <arm_group_label>F520 3mg/kg multiple dosing, every 3 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female 18-65 years of age;&#xD;
&#xD;
          2. Histologically or cell confirmed advanced, unresectable or metastatic disease tumor&#xD;
             and failure to standard therapies or lack of standard therapy(disease progress or&#xD;
             failed to tolerate the toxicity, such as chemotherapy, targeted therapy, and other&#xD;
             immunotherapies other than PD-1/PD-L1);&#xD;
&#xD;
          3. Agree to provide archived tumor tissue specimens or fresh tissue specimens;&#xD;
&#xD;
          4. ECOG performance status of 0 or 1;&#xD;
&#xD;
          5. Life expectancy ≥ 12 weeks.;&#xD;
&#xD;
          6. At least one measurable and evaluable tumor lesion (in accordance with international&#xD;
             working group criteria/RANO/cheson 2007)；&#xD;
&#xD;
          7. Adequate laboratory parameters during the screening period as evidenced by the&#xD;
             following（No blood components and cell growth factors are allowed within 28 days prior&#xD;
             to screening）:&#xD;
&#xD;
             routine blood tests: Absolute neutrophil count ≥1.0×109/L ;Platelets&#xD;
             ≥100×109/L;Hemoglobin ≥ 9.0 g/dL; Liver function：Total bilirubin (TBIL) ≤1.5×upper&#xD;
             limit of normal (ULN), ALT and AST ≤2.5ULN; for subjects with liver metastases,&#xD;
             alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5×ULN, Total&#xD;
             bilirubin (TBIL) ≤3×upper limit of normal (ULN); Renal function CCr≤1.5×ULN，Creatinine&#xD;
             clearance≥50 mL/min;&#xD;
&#xD;
          8. Thyroid function indicators: thyroid-stimulating hormone (TSH) and free thyroxine&#xD;
             (FT3/FT4) are within the normal range;&#xD;
&#xD;
          9. Understand study procedures and contents, and voluntarily sign the written informed&#xD;
             consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with any active autoimmune disease or history of autoimmune disease,&#xD;
             including but not limited to the following: Immune-related neurological diseases,&#xD;
             multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome,&#xD;
             myasthenia gravis, systemic lupus erythematosus, connective tissue disease,&#xD;
             scleroderma, inflammatory bowel disease including Crowe Enthusiasm and ulcerative&#xD;
             colitis, autoimmune hepatitis, toxic epidermal necrolysis or Stevens-Johnson syndrome；&#xD;
&#xD;
          2. Presence of symptomatic central nervous system (CNS) metastases；&#xD;
&#xD;
          3. Concurrent medical condition requiring the use of immunosuppressive medications, or&#xD;
             immunosuppressive doses of systemic or absorbable topical corticosteroids. Doses &gt; 10&#xD;
             mg/day prednisone or equivalent are prohibited within 14 days before entering the&#xD;
             group and during the study period;&#xD;
&#xD;
          4. Prior radiotherapy, systemic chemotherapy hormone therapy, surgery or target therapy&#xD;
             within 4 weeks or 5 half-lives(whichever is longer) before the study drug&#xD;
             administration, or any unresolved AEs &gt; CTC-AE Grade 1;&#xD;
&#xD;
          5. Autologous hematopoietic stem cell transplantation (ASCT) has been completed at least&#xD;
             3 months before receiveing first dose;&#xD;
&#xD;
          6. Known history of hypersensitivity to macromolecular protein preparation or any&#xD;
             components of the F520 formulation；&#xD;
&#xD;
          7. Patients receiving any anti-infection vaccine within 4 weeks before enrollment;&#xD;
&#xD;
          8. History or concurrent with other malignant disease, except completely cured basal cell&#xD;
             skin cancers and carcinoma in situs of cervix;&#xD;
&#xD;
          9. Uncontrolled clinically significant heart disease, including but not limited to the&#xD;
             following: (1) &gt;2 NYHA 2 congestive heart failure; (2) unstable angina, (3) myocardial&#xD;
             infarction within the past 1 year; (4) clinically significant supraventricular&#xD;
             arrhythmia or ventricular arrhythmia requirement for treatment or intervention;&#xD;
&#xD;
         10. Active infection（needing therapy） or an unexplained fever &gt; 38.5°C during screening or&#xD;
             before the first scheduled day of dosing (subjects with tumor fever may be enrolled at&#xD;
             the discretion of the investigator);&#xD;
&#xD;
         11. Patients with active pulmonary tuberculosis; patients who previously had active&#xD;
             pulmonary tuberculosis;&#xD;
&#xD;
         12. History of immunodeficiency (HIV) or active hepatitis(Hepatitis B: HBsAg, Anti-HBs,&#xD;
             HBeAg, Anti-HBe, Anti-HBc,HBV-DNA; Hepatitis C: Anti-HCV,HCV-RNA)&#xD;
&#xD;
         13. Participation in a clinical study or less than 1 month from the last dose of&#xD;
             investigational drug to sign ICF;&#xD;
&#xD;
         14. History of PD-1/PD-L1 or CTLA-4 therapy;&#xD;
&#xD;
         15. Patients with drug abuse history or alcohol addiction history;&#xD;
&#xD;
         16. Patients with current or previous interstitial lung diseases;&#xD;
&#xD;
         17. Female and male who have reproductive potential must be willing and able to employ a&#xD;
             highly effective method of birth control/contraception to prevent pregnancy while on&#xD;
             treatment and for at least 6 months after receiving the last dose of study treatment.&#xD;
&#xD;
         18. Other factors that may lead to the termination of the participation in the study at&#xD;
             the discretion of the investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shaohong Yin</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <zip>276006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaohong Yin</last_name>
      <phone>86-15265901803</phone>
      <email>yinshaohong@lunan.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 31, 2018</study_first_submitted>
  <study_first_submitted_qc>September 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

